Shuttle Pharmaceuticals Stock Soars 145.19% on Ropidoxuridine Trial Progress

On May 9, 2025, Shuttle's stock surged by 145.19% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Shuttle Pharmaceuticals has made substantial progress in its Phase 2 clinical trial for Ropidoxuridine, an orphan drug. The company has achieved nearly 50% enrollment in the initial randomized portion of the trial, which is a critical milestone in the drug's development. This progress has been well-received by the market, contributing to the recent surge in the company's stock price.

The Phase 2 clinical trial is designed to evaluate the safety and efficacy of Ropidoxuridine at two different dose levels, with 40 patients randomized into the study. The trial's progress indicates that the drug is on track to meet its enrollment goals, which is a positive sign for its potential approval by the FDA.

Shuttle Pharmaceuticals' announcement of the enrollment milestone has generated significant interest among investors, who see the potential for the drug to address unmet medical needs and gain market approval. The company's focus on orphan drugs, which target rare diseases, positions it well in a niche market with high demand and limited competition.